Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease.

Abstract

Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative disorders, are well-known underlying diseases in LCDD. Some chemotherapy regimens have been reported, but both evidence-based treatment and management for LCDD have yet to be established. We herein report three cases of LCDD treated with lenalidomide-based therapy, resulting in hematologic responses accompanied by a significant reduction in proteinuria and improvement in the renal function. We recommend lenalidomide-based therapy for renal impairment caused by LCDD.

• Authors: Satoshi Kimura, Hiroshi Ohkawara, Kazuei Ogawa, Mizuko Tanaka, Takahiro Sano, Kayo Harada-Shirado, Hiroshi Takahashi, Koki Ueda, Akiko Shichishima-Nakamura, Hayato Matsumoto, Kazuhiko Ikeda, Junichiro James Kazama, Yuko Hashimoto, Takayuki Ikezoe
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 57 Issue 24 Pg. 3651-3657 (Dec 15 2018) ISSN: 1349-7235 [Electronic] Japan
• PMID: 30101913 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulin Light Chains
• Immunologic Factors
• Lenalidomide

Topics

• Aged
• Humans
• Immunoglobulin Light Chains
• Immunologic Factors (therapeutic use)
• Lenalidomide (therapeutic use)
• Male
• Paraproteinemias (complications)
• Proteinuria (drug therapy)
• Renal Insufficiency (drug therapy, etiology)